News and Events
Are you using the right reagents for Hemophilia testing?
Hemophilia testing is complicated – DiaPharma scientists can help you choose the right assays for your testing needs. We offer a variety of kits and reagents to measure FVIII and FIX. Contact us to learn more.
COAMATIC® FVIII (K822585)
COATEST® SP FVIII (K824086)
COATEST® SP4 FVIII (K824094)
● Contains bovine FIXa + FX reagents
● FDA-cleared
Technochrom FVIII 2G on Ceveron® s100*
● Automated sensitive FVIII assay
Technoclone Factor FVIII Inhibitor (Bethesda)* – fully automated coming soon!
Ceveron® TGA RB on Ceveron® s100*
● Automated, standardized thrombin generation assay
● Optimized for measurement of bleeding tendency, hemophilia research & development
● Explore thrombin generation assay options on the Ceveron s100
● Chromogenic FIX for Hemophilia B research
● Accurate and easy to use
*For research use only in US and Canada. Not for use in diagnostic procedures.
Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
An alternative is the M30 Apoptosense® ELISA*.
What is the M30 Apoptosense® ELISA?
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
-
The standardization of NET measurements, a work in progress.
Posted: October 5, 2023
-Contributed by Abi Kasberg, PhD and Olivia Stricker, PhD Neutrophil extracellular traps (NETs) are an amazing participant of the innate immune system. In a first line of defense, neutrophils expel decondensated chromatin into the extracellular matrix to trap invading pathogens in a mechanism called NETosis. NETs are made up of DNA, histones, and granule…
-
A Review of the XXXVth International Symposium on Technical Innovations in Laboratory Hematology 2023 (ISLH 2023)
Posted: September 8, 2023
David L. McGlasson, MS, MLS(ASCP) The most recent ISLH meeting was held in New Orleans, LA May 11-13, 2023. The conference had many State-of-the-Art sessions and I concentrated on the hemostasis/thrombosis presentations. On the first day, Katrien Devreese MD, PhD, Ghent University Hospital, Belgium gave an excellent presentation on the current Diagnosis of Acquired Thrombotic…
-
Anticipated NASH Drug Approval will Require Expanded Non-Invasive Testing: NASH-TAG 2023 Takeaways
Posted: April 19, 2023
-Contributed by Abi Kasberg, PhD High levels of enthusiasm and excitement were shared at this year’s NASH-TAG meeting in Deer Valley, Utah, regarding the future of the NASH landscape. This was in large part due to the announcement of positive data from two phase 3 clinical trials for new NASH drugs: Madrigal’s Resmetirom and Intercept’s…
-
SOT 2023, Recap through a DiaPharma lens
Posted: April 19, 2023
-Olivia Stricker, PhD Meetings are back baby! This was the first event that I have been to since the pandemic where it felt 100% back to normal. It was great to get back to it and have others there to get back to it with. In heading to Nashville, DiaPharma/I was in search of answers…
-
Should Direct Oral Anticoagulants (DOAC) be Used in Individuals with Antiphospholipid Syndrome (aPS) vs Long Term Warfarin Treatment?
Posted: April 14, 2023
David L. McGlasson, MS, MLS(ASCP) At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” The HTRS session was moderated by Ayesha N. Zia MD, MSCS and Bethany T. Samuelson, MD, and included three presenters: Introduction to Science: Stephan Moll, MD, University of…
-
Grant Opportunity from DiaPharma
Posted: April 13, 2023
Why isn’t this being funded?! Thoughts from HTRS 2023, and a grant opportunity from DiaPharma Jennifer J. Kiblinger Scientific Director The HTRS 2023 Scientific Symposium gave new insights in hemostasis and thrombosis, from health justice initiatives to the latest in antiphospholipid antibody testing. There were lively and insightful debates, even one on how many steel…